MX2021002017A - Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion. - Google Patents

Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion.

Info

Publication number
MX2021002017A
MX2021002017A MX2021002017A MX2021002017A MX2021002017A MX 2021002017 A MX2021002017 A MX 2021002017A MX 2021002017 A MX2021002017 A MX 2021002017A MX 2021002017 A MX2021002017 A MX 2021002017A MX 2021002017 A MX2021002017 A MX 2021002017A
Authority
MX
Mexico
Prior art keywords
disorders
roluperidone
negative symptoms
neuroplasticity
treat negative
Prior art date
Application number
MX2021002017A
Other languages
English (en)
Inventor
Remy Henri Luthringer
Original Assignee
Minerva Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Neurosciences Inc filed Critical Minerva Neurosciences Inc
Publication of MX2021002017A publication Critical patent/MX2021002017A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Abstract

La presente solicitud se refiere al uso de roluperidona, es decir, Compuesto (I): (ver Fórmula) y sales, solvatos, composiciones farmacéuticas y formas de dosificación del mismo, para su uso en métodos de tratamiento de síntomas y trastornos negativos (por ejemplo, trastornos del autismo, ambliopía, trastornos de la personalidad, lesión cerebral traumática), así como para aumentar la neuroplasticidad y promover la neuroprotección en sujetos que lo necesitan.
MX2021002017A 2018-08-21 2019-08-21 Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion. MX2021002017A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862720667P 2018-08-21 2018-08-21
US201962831535P 2019-04-09 2019-04-09
PCT/US2019/047555 WO2020041504A1 (en) 2018-08-21 2019-08-21 Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection

Publications (1)

Publication Number Publication Date
MX2021002017A true MX2021002017A (es) 2021-04-28

Family

ID=67874530

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002017A MX2021002017A (es) 2018-08-21 2019-08-21 Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion.

Country Status (14)

Country Link
US (2) US11083723B2 (es)
EP (1) EP3840835A1 (es)
JP (1) JP2022511266A (es)
KR (1) KR20210061349A (es)
CN (1) CN112955219A (es)
AU (1) AU2019326525A1 (es)
BR (1) BR112021002654A2 (es)
CA (1) CA3108882A1 (es)
CL (2) CL2021000424A1 (es)
GB (1) GB2591667A (es)
IL (1) IL280765A (es)
MA (1) MA53437A (es)
MX (1) MX2021002017A (es)
WO (1) WO2020041504A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201704332YA (en) 2014-12-02 2017-06-29 Minerva Neurosciences Inc Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
JP2020525436A (ja) 2017-06-21 2020-08-27 ミネルバ・ニューロサイエンシズ・インコーポレイテッド 胃耐性制御放出経口剤形
EP3840835A1 (en) * 2018-08-21 2021-06-30 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0325063B1 (en) 1988-01-21 1994-03-09 Merrell Dow Pharmaceuticals Inc. Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia
KR927002347A (ko) 1989-10-27 1992-09-03 레이몬드 지. 아너 (n-프탈이미도알킬) 피페리딘
RU2257384C2 (ru) 2000-02-29 2005-07-27 Мицубиси Фарма Корпорейшн Новые производные циклического амида
AR057350A1 (es) 2005-06-06 2007-11-28 Merck Sharp & Dohme Derivados de ciclohexanosulfonilo como inhibidores de glyt1 para tratar esquizofrenia. composiciones farmaceuticas
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
EP2528938A4 (en) 2010-01-27 2013-10-23 Childrens Medical Center PROANGIOGENIC FRAGMENTS OF PROMININ 1 AND USES THEREOF
FI3135286T3 (fi) * 2010-07-20 2023-11-15 Minerva Neurosciences Inc Menetelmiä syklisten amidijohdannaisten käyttämiseksi skitsofrenian ja sen oireiden hoitamisessa
HUE058736T2 (hu) * 2010-07-20 2022-09-28 Minerva Neurosciences Inc Gyûrûs amidszármazékok alkalmazási módszerei szigma receptor közvetített rendellenességek kezelésére
US8937900B2 (en) 2010-07-20 2015-01-20 Qualcomm Incorporated Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies
EP2468264A1 (en) 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
WO2012123922A1 (en) 2011-03-17 2012-09-20 Lupin Limited Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
WO2015191554A1 (en) 2014-06-09 2015-12-17 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
SG11201704332YA (en) 2014-12-02 2017-06-29 Minerva Neurosciences Inc Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
SG10202011470UA (en) 2016-05-25 2021-01-28 Mitsubishi Tanabe Pharma Corp Compositions and methods for treating negative symptoms in non-schizophrenic patients
JP2020525436A (ja) 2017-06-21 2020-08-27 ミネルバ・ニューロサイエンシズ・インコーポレイテッド 胃耐性制御放出経口剤形
EP3840835A1 (en) * 2018-08-21 2021-06-30 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection

Also Published As

Publication number Publication date
GB2591667A (en) 2021-08-04
GB202103819D0 (en) 2021-05-05
WO2020041504A1 (en) 2020-02-27
EP3840835A1 (en) 2021-06-30
IL280765A (en) 2021-04-29
MA53437A (fr) 2021-06-30
US20220096455A1 (en) 2022-03-31
BR112021002654A2 (pt) 2021-05-04
US11083723B2 (en) 2021-08-10
JP2022511266A (ja) 2022-01-31
US20200061046A1 (en) 2020-02-27
AU2019326525A1 (en) 2021-03-04
KR20210061349A (ko) 2021-05-27
CA3108882A1 (en) 2020-02-27
CN112955219A (zh) 2021-06-11
CL2023001580A1 (es) 2023-11-03
CL2021000424A1 (es) 2021-07-09

Similar Documents

Publication Publication Date Title
MX2019004616A (es) Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina.
PH12019502269A1 (en) Quinazoline derivatives for the treatment of viral infections and further diseases
EA201990665A1 (ru) Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака
CR20210335A (es) Compuestos de 2-formil-3-hidroxifeniloximetilo capaces de modular la hemoglobina
MY190408A (en) Compositions and methods for treating cns disorders
MX2019012818A (es) Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos.
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
EA201590655A8 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
BR112017026739A2 (pt) compostos para uso no tratamento de distúrbios neuromusculares
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
BR112015001847A2 (pt) composições e tratamento para doenças e distúrbios nos olhos
EA201000603A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
MX2021002017A (es) Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion.
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
PH12021550872A1 (en) Therapeutic compounds
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
WO2018154118A3 (en) Aromatic compounds which enhance notch signaling, for use in therapy
MX2021002322A (es) Nuevos metodos.
MX2020010552A (es) Derivados de bumetanida para el tratamiento de la hiperhidrosis.
CR20230177A (es) Compuestos y composiciones como moduladores de señalización tlr
MX2019014272A (es) Compuestos policiclicos y usos de los mismos.
MX2021011596A (es) Compuestos y composiciones como moduladores de se?alizacion tlr.
MX2021006209A (es) Montelukast para el tratamiento de la osteoartritis erosiva de la mano.
BR112015007095A8 (pt) derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados, composição farmacêutica compreendendoos e uso dos referidos derivados
EA201792170A1 (ru) Производные индола